Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | HCK | P08631 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.39 |
| ▸ | PRKDC | P78527 | 1/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.39 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19355446 | 0.81 | CRHR1 (0.43) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL12235181 | 0.79 | P2RX3 (0.35) | PIK3CAP2RX3P2RX2 | |
| SCHEMBL14416657 | 0.79 | CYP1A2 (0.44) | PIK3CAMTORCYP1A2P2RX3P2RX2 | |
| SCHEMBL10216223 | 0.79 | P2RX3 (0.42) | PIK3CAP2RX3P2RX2 | |
| SCHEMBL13510193 | 0.79 | P2RX3 (0.38) | CYP1A2P2RX3P2RX2HSP90AA1HSP90B1 | |
| SCHEMBL2611023 | 0.78 | P2RX3 (0.51) | P2RX3P2RX2 | |
| SCHEMBL28407976 | 0.76 | P2RX3 (0.64) | P2RX3P2RX2 | |
| SCHEMBL3816071 | 0.74 | KMT2A (0.52) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL8888 | 0.74 | QPCT (0.40) | PIK3CAPIK3CDABL1EGFRHCK | |
| SCHEMBL25165378 | 0.73 | PDE4B (0.39) | P2RX3P2RX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| WO-2020157491-A1 | G-A CROSSLINKING CYTOTOXIC AGENTS | FEMTOGENIX LIMITED (GB) | 2020-08-06 | — | — | WO | disclosed |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | PETER MACCALLUM CANCER INSTITUTE (AU) | 2019-06-27 | — | — | US | disclosed |
| US-10308653-B2 | Diazepane derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-10226434-B2 | Design, synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus activity | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | US | disclosed |
| WO-2008086188-A2 | THIOPHENE CARBOXAMIDES AS FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-4818277-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-04-04 | — | — | US | disclosed |
| EP-0035893-B1 | HERBICIDAL BENZENE- AND PYRIDINE-SULFONAMIDE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-11-21 | — | — | EP | disclosed |
| EP-0035893-A2 | Herbicidal benzene- and pyridine-sulfonamide derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185092-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | PIK3CA 736/4885PIK3CD 1472/4885ABL1 1707/4885 |
| US-10226434-B2 | Design, synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus activity | RNGTT, ACE, ACE2 | PIK3CA 1837/4885PIK3CD 1984/4885ABL1 3970/4885 |
| US-10308653-B2 | Diazepane derivatives and uses thereof | BRDT, BRD4, BAZ2A | PIK3CA 4321/4885PIK3CD 3409/4885ABL1 3150/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PIK3CA 1180/4885PIK3CD 1684/4885ABL1 190/4885 |
| US-20070225287-A1 | Substituted Arylpyrazines | CRHR1, CRHR2, CRH | PIK3CA 4758/4885PIK3CD 4796/4885ABL1 897/4885 |
| US-20180153859-A1 | METHODS OF TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES BASED ON APOE4 GENOTYPE | CHRNA2, ACACA, CHAT | PIK3CA 3196/4885PIK3CD 4028/4885ABL1 4116/4885 |
| US-20180153860-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | CHAT, ACHE, CHRNA2 | PIK3CA 4285/4885PIK3CD 3829/4885ABL1 4455/4885 |
| US-20190192532-A1 | COMBINATION THERAPY OF BROMODOMAIN INHIBITORS AND CHECKPOINT BLOCKADE | BRD4, BRD3, BRPF3 | PIK3CA 3311/4885PIK3CD 3131/4885ABL1 859/4885 |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | PI4KA, DMPK, PDPK1 | PIK3CA 9/4885PIK3CD 11/4885ABL1 950/4885 |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | PIK3CA 2553/4885PIK3CD 3996/4885ABL1 3500/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | PIK3CA 1845/4885PIK3CD 2769/4885ABL1 287/4885 |
| US-20200338074-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PIK3CA 1180/4885PIK3CD 1684/4885ABL1 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.